D-dimer In Patients With atRial Fibrillation rEceiving antiCoagulation Therapy

The Role of D-dimer in Patients With Atrial Fibrillation Receiving Anticoagulation Therapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03280641

Acronym

DIRECT

Enrollment

1194

Registered

2017-09-12

Start date

2015-08-09

Completion date

2017-09-01

Last updated

2017-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Strokes Thrombotic

Brief summary

This is a sigle-center, prospective study to evaluate the role of D-Dimer testing in patients with atrial fibrillation receiving Dabigatran or warfarin anticoagulation therapy.

Detailed description

Patients with atrial fibrillation receiving Dabigatran or warfarin anticoagulation therapy was screened and signed to two group: Dabigatran group and Warfarin group. D-dimer test was analyzed before and 3 months after anticoagulation starting specificly. Patients were followed-up for at least 12 months,and clinical outcomes, including thrombotic events major bleeding events and all-cause deaths were recorded during follow-up period.

Interventions

DRUGDabigatran Etexilate 110mg

Dabigatran Etexilate 110mg, BID

DRUGWarfarin Sodium

Target INR:1.6-3.0

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Inclusion criteria

* Non-valvular atrial fibrillation * Receiving oral anticoagulation therapy and have good compliance

Exclusion criteria

* Life expectancy less than 1 year * Thrombosis or major bleeding history within 3 months * Refusal to Participate

Design outcomes

Primary

Measure	Time frame	Description
Cardiovascular events	12 months	Thrombotic events, cardiovascular deaths, major bleeding events

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026